Preventing Rejection With Prograf® (tacrolimus capsules and injection)

Prograf is an immunosuppressant approved for the prevention of rejection in people who have received a liver, kidney, or heart transplant. Anti-rejection medications like Prograf are essential to the success of transplantation. In fact, since approval for rejection prevention for liver transplantation in 1994, for kidney transplantation in 1997, and for heart transplantation in 2006, Prograf has become a treatment that recipients and healthcare professionals alike can believe in.

Read Prograf and You to learn more about what Prograf can do for you.

Full Prescribing Information

Important Safety Information About Prograf^®

Prograf^® (tacrolimus) is approved for the prevention of rejection in patients who have received a liver, kidney, or heart transplant. Only physicians and facilities specializing in transplantation should manage patients taking Prograf. Anti-rejection medications may result in an increased possibility of developing an infection or lymphoma, a type of cancer.

In clinical studies, up to 22% of patients taking Prograf developed insulin-dependent diabetes after transplant, but in some patients, after two years, insulin was no longer required. Black and Hispanic kidney transplant patients were at an increased risk.

Prograf has been associated with toxicity to the kidneys and nervous system. Common side effects are tremor, headache, insomnia, high blood pressure, diarrhea, nausea, constipation, stomach pain, changes in kidney function, high blood sugar, low white cell count, infection, and high cholesterol/lipid levels.

Prograf should not be used in patients allergic to tacrolimus. Prograf injection should not be used in patients allergic to castor oil.

Only your healthcare professional can weigh the risks and benefits of a prescription medication and decide which medication is the right one for you.

Please see the full prescribing information.

Print this page